HyTest Ltd., Turku, 20520, Finland.
Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, 119991, Russia.
Biochemistry (Mosc). 2019 Nov;84(11):1346-1358. doi: 10.1134/S0006297919110105.
Neprilysin (NEP) is a zinc-dependent metalloproteinase that exists in organisms in both transmembrane and soluble forms. NEP substrates are involved in regulating the cardiovascular and nervous systems. In this review, we discuss some of the biochemical characteristics and physiological functions of this enzyme with special emphasis on the use of NEP as a therapeutic target. The history and various physiological aspects of applying NEP inhibitors for treating heart failure and attempts to increase NEP activity when treating Alzheimer's disease using gene and cell therapies are described. Another important issue discussed is the role of NEP as a potential marker for predicting the risk of cardiovascular disease complications. The diagnostic and prognostic performance of soluble NEP in various types of heart failure is analyzed and presented. We also discuss the methods and approaches for measuring NEP activity for prognosis and diagnosis, as well as a possible new role of natriuretic peptides (NEP substrates) in cardiovascular diagnostics.
脑啡肽酶(NEP)是一种锌依赖性金属蛋白酶,以跨膜和可溶性形式存在于生物体内。NEP 的底物参与调节心血管和神经系统。在这篇综述中,我们讨论了这种酶的一些生化特性和生理功能,特别强调了将 NEP 作为治疗靶点的应用。描述了 NEP 抑制剂在心力衰竭治疗中的应用历史和各种生理方面,以及使用基因和细胞疗法增加 NEP 活性治疗阿尔茨海默病的尝试。另一个重要的讨论问题是 NEP 作为预测心血管疾病并发症风险的潜在标志物的作用。分析并介绍了可溶性 NEP 在各种类型心力衰竭中的诊断和预后性能。我们还讨论了用于预后和诊断的 NEP 活性测量方法和途径,以及神经肽(NEP 底物)在心血管诊断中的可能新作用。